Clinical Trial Update: Study to Determine Effective Dosing of Fondaparinux in Obese Persons [Phase 1]

View source ↗

Summary

This clinical trial update indicates that a Phase 1 study to determine effective dosing of fondaparinux in adults with morbid obesity was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Morbid Obesity

Drugs mentioned

• Fondaparinux (fondaparinux)

Snippet

Sponsor: Indiana University School of Medicine | Conditions: Morbid Obesity | Phase 1 | Status: WITHDRAWN